Physicians' Academy for Cardiovascular Education

CV Inflammation

Inflammation is receiving increasing attention for a potential role in residual CV risk. Follow recent insights into the importance of inflammation of CVD.

The burden of residual CV risk in the statin era

5' education - Jan. 6, 2020 - Erin Bohula, MD

Single dose colchicine prior to PCI reduces rise in inflammation, but does not give reduction in MI and MACE

3' education - Nov. 25, 2019 - Binita Shah - AHA 2019, Philadelphia

Succesful repurposing of an old anti-inflammatory drug for a new application

3' education - Nov. 16, 2019 - Aruna Pradhan, MD - AHA 2019, Philadelphia

Treatment with anti-inflammatory agent reduces both first and recurrent events post-MI

3' education - Nov. 16, 2019 - Jean-Claude Tardif, MD, Canada - AHA 2019, Philadelphia

CRP levels associated with risk of cancer in stable CVD

5' education - Oct. 14, 2019 - Paris, France - Cilie van ’t Klooster, MD

Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition

10' education - Aug. 31, 2019 - Prof. Kausik Ray, MD

Challenges in targeting residual risk in diabetic patients, post ACS

10' education - Sep. 25, 2019 - Prof. Peter Libby, MD

Understanding and managing obesity-related HFpEF

10' education - July 22, 2019 - Milton Packer, MD

Effect of IL-1β inhibition on lung cancer sheds new light on the role of inflammation

3' education - May 28, 2019 - EAS 2019, Maastricht - Paul Ridker, MD

Lp(a) lowering with PCSK9 inhibitor not enough to tackle artery wall inflammation

3' education - Dec. 3, 2018 - Prof. Erik Stroes, MD

Neutral study with methotrexate offers interesting insights on CV-relevant inflammatory pathway

3' education - Nov. 11, 2018

The predictive role of biomarkers in CV risk assessment

10' education - Oct. 23, 2018 - Nina Paynter, PhD - Boston, MA, USA

Understanding epigenetics: The potential rationale for BET inhibition in management of CVD

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Jorge Plutzky, MD – Boston, MA, USA

What is the situation one year after the presentation about the CANTOS trial?

10' education - Aug. 26, 2018 - Munich, Germany - Prof. Paul Ridker, MD - Boston, MA, USA

The real residual risk in patients with CVD & diabetes: The promise of epigenetics

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Erik Stroes, MD - Amsterdam, The Netherlands
Also as CME accredited e-learning

The CANTOS trial: Implications for the management of patients with residual risk

10' education - Nov. 16, 2017 - Prof. Paul Ridker - Boston, MA, USA - Online CME

Anti-inflammatory therapy in the prevention of cardiovascular disease

10' education - Nov. 16, 2017 - Prof. Peter Libby, USA

No evidence that anti-inflammatory treatment prevents progression to T2DM in CANTOS trial

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Brendan Everett, MD - Boston, MA, USA

Anti-inflammatory treatment also gives MACE reduction in high-risk patients with kidney disease

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Paul Ridker - Boston, MA, USA
Also as CME e-learning

Inflammation & CVD: Translating insights from vascular biology to the clinic

10' education - Nov. 16, 2017 - Prof. Peter Libby, USA - Online CME
Also as CME accredited e-learning

The new era of residual risk reduction

10' education - Nov. 16, 2017 - Prof. Erik Stroes - Amsterdam, The Netherlands - Online CME

The patient with inflammatory residual risk: Who is it?

10' education - Nov. 16, 2017 - Prof. Wolfgang Koenig - Munich, Germany - Online CME

There is hope for treatment of HFpEF

3' education - Nov. 24, 2017 - WCN congress, Amsterdam, The Netherlands - Prof. Carolyn Lam, MD - Singapore

Analogous to LDL-c, the lower the better also seems true for inflammation

3' education - Nov. 14, 2017 - Paul Ridker, Boston, MA, USA

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

5' education - Aug. 27, 2017

Interleukin-1 Beta-Inhibition nach akutem Koronarsyndrom – ein neuer therapeutischer Ansatz

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Proof-of-Concept Studie: Zusätzliche therapeutische Strategie neben der Lipidsenkung reduziert das kardiovaskuläre Risiko

5' education - Sep. 29, 2017 - ESC 2017, Barcelona, Spain

Proof-of-concept trial may provide additional treatment option beyond lipid lowering for CV risk reduction

5' education - Sep. 29, 2017 - ESC 2017, Barcelona, Spain

Pre-PCI P2Y12 inhibitor administration and stent-induced endothelial dysfunction and inflammation in ACS

Literature - Jan. 8, 2020 - Schnorbus B et al., - Eur Heart J. 2020

Patients with ACS who received prasugrel before PCI, showed less endothelial dysfunction and platelet aggregation, while those on clopidogrel and ticagrelor did not, nor did treatment after PCI.

The burden of residual CV risk in the statin era

5' education - Jan. 6, 2020 - Erin Bohula, MD
Erin Bohula explains which determinants of residual CV risk we nowadays know and presents study results on how to target these.

Erin Bohula explains which determinants of residual CV risk we nowadays know and presents study results on how to target these.

Single dose colchicine prior to PCI reduces rise in inflammation, but does not give reduction in MI and MACE

3' education - Nov. 25, 2019 - Binita Shah - AHA 2019, Philadelphia
The COLCHICINE-PCI trial investigated whether a single dose of the anti-inflammatory agent colchicine, given prior to PCI, resulted in reduced vascular inflammation and myocardial injury after PCI.

AHA 2019 The COLCHICINE-PCI trial investigated whether a single dose of the anti-inflammatory agent colchicine, given prior to PCI, resulted in reduced vascular inflammation and myocardial injury after PCI.

Succesful repurposing of an old anti-inflammatory drug for a new application

3' education - Nov. 16, 2019 - Aruna Pradhan, MD - AHA 2019, Philadelphia
Pradhan was the discussant of the COLCOT trial. She put the results in the broader perspective of managing inflammation as a means to lower CV risk.

AHA 2019 Pradhan was the discussant of the COLCOT trial. She put the results in the broader perspective of managing inflammation as a means to lower CV risk.

Treatment with anti-inflammatory agent reduces both first and recurrent events post-MI

3' education - Nov. 16, 2019 - Jean-Claude Tardif, MD, Canada - AHA 2019, Philadelphia
Dr. Tardif summarizes the study design and results of the COLCOT trial, in which colchicine treatment was found to lower a composite endpoint in patients soon after MI.

AHA 2019 Dr. Tardif summarizes the study design and results of the COLCOT trial, in which colchicine treatment was found to lower a composite endpoint in patients soon after MI.

Generic anti-inflammatory drug lowers ischemic events in patients with recent MI

News - Nov. 16, 2019

AHA 2019 Daily colchicine lowered ischemic events, mostly urgent revascularization, in patients with an MI less than 30 days ago, in the COLCOT trial. Colchicine was well-tolerated.

CRP levels associated with risk of cancer in stable CVD

5' education - Oct. 14, 2019 - Paris, France - Cilie van ’t Klooster, MD
Steven Hageman asks Cilie van 't Klooster about her study on the relationship between CRP levels and risk of incident cancer and recurrent CV events in subjects with stable CVD in the SMART-cohort.

CSI Paris Steven Hageman asks Cilie van 't Klooster about her study on the relationship between CRP levels and risk of incident cancer and recurrent CV events in subjects with stable CVD in the SMART-cohort.

Identification of determinants of iron deficiency in worsening HF

Literature - Oct. 10, 2019 - Van der Wal H et al., - Eur Heart J 2019

Data of the BIOSTAT-CHF cohort suggest that the etiology of ID in worsening HF is multifactorial and may involve a combination of reduced iron uptake, impaired iron storage and iron loss.

Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition

10' education - Aug. 31, 2019 - Prof. Kausik Ray, MD
Prof. Ray describes the high residual CV risk in post-ACS diabetes patients, and how BET inhibition with apabetalone may reduce this residual risk and thereby prevent CV events.

Prof. Ray describes the high residual CV risk in post-ACS diabetes patients, and how BET inhibition with apabetalone may reduce this residual risk and thereby prevent CV events.

Challenges in targeting residual risk in diabetic patients, post ACS

10' education - Sep. 25, 2019 - Prof. Peter Libby, MD
Prof. Libby discusses the inflammatory residual risk in diabetes patients and explains how epigenetic modulation of inflammatory genes can reduce this risk.

Prof. Libby discusses the inflammatory residual risk in diabetes patients and explains how epigenetic modulation of (inflammatory) gene transcription can potentially reduce CV risk.

Residual inflammatory risk associated with IL-6 and IL-18 after IL-1β inhibition

Literature - Sep. 24, 2019 - Ridker PM et al. - Eur Heart J. 2019

A biomarker analysis in a subgroup of CANTOS participants shows that plasma levels of cytokines IL-6 and IL-18 are related to future CV risk both before and after treatment with canakinumab.

CRP not only related to recurrent CV events, but also to cancer in patients with stable CVD

Literature - Sep. 11, 2019 - Van ’t Klooster CC et al. - Eur Heart J 2019

Data of a prospective cohort suggest that chronic systemic low-grade inflammation, as measured by CRP, plays a role in development of cancer, particularly of the lung, in those with stable CVD.